Drugmakers have 26 vaccines in clinical trials, he noted. Of the applicants, a dozen have reached phase II trials and six that are in phase III undergoing large-scale efficacy and safety testing. For Europeans, US regulatory approval of an initial vaccine would allow them to be vaccinated by October.“For context, it took hepatitis B – the disease with the most number of attempts – decades to reach the number of developments that COVID-19 sparked in just a few quarters,” Struyven said.
Dr Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, expressed hope last month that a “safe and effective” vaccine would be available in late fall or early fall. winter. But he and other experts have warned that scientists may need to develop multiple vaccines to beat COVID-19. A recent study determined that there isinvolving different groups of symptoms.
The coronavirus has spread like wildfire across the United States, most recently to the southern and western states. The pandemic is now “extraordinarily widespread”Dr. Deborah Birx, coordinator of the White House Coronavirus Task Force, told CNN.
As the number of cases increases and containment seems unlikely, economic recovery largely depends on the availability of a vaccine. Struyven based its schedule for a vaccine on the large pipeline of treatments, promising preliminary results and increased funding in late stage trials, as well as regulators’ flexibility in approval.
A decision by the FDA to approve a vaccine by the end of the year would give the economy a major boost, ending the “scarring effects of bankruptcies and layoffs,” according to Goldman.
While Goldman has said drugmakers are moving quickly to develop possible vaccines, the Wall Street company has also sought to temper expectations about their effectiveness in fighting the virus.
“Early approval[delaFDA}doesnotimplyfulleffectivenessorlong-termprotection”statedStruyven[FDA}approvaldoesnotimplyfulleffectivenessorlong-runprotection”Struyvensaid[delaFDA}n’impliquepasunepleineefficacitéouuneprotectionàlongterme »adéclaréStruyven[FDA}approvaldoesnotimplyfulleffectivenessorlong-runprotection »Struyvensaid